teplizumab

News

Sanofi seeks use of type 1 diabetes drug in younger kids

Sanofi could be months away from wider US approval for Tzield, its drug for delaying the progression of type 1 diabetes, in children as young as one.

News

Provention finally gets FDA nod for type 1 diabetes drug tep...

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-m

News

FDA sets August decision date for Provention's type 1 diabet...

Shares in Provention Bio cratered last July when the FDA turned down its marketing application for type 1 diabetes therapy teplizumab.

News

FDA rejects Provention's type 1 diabetes drug teplizumab

The FDA indicated something was not well with Provention Bio's filing for type 1 diabetes therapy teplizumab in April when it delayed its review.

News

Provention faces delay in FDA review of diabetes prevention ...

The FDA says it has uncovered "deficiencies" in the marketing application for Provention Bio's much-anticipated drug teplizumab for the prevention of

Sanofi seeks use of type 1 diabetes drug in younger kids

Provention finally gets FDA nod for type 1 diabetes drug tep...

FDA sets August decision date for Provention's type 1 diabet...

FDA rejects Provention's type 1 diabetes drug teplizumab

Provention faces delay in FDA review of diabetes prevention ...

J&J jumps on the MFN pricing train

How to meet your physicians where they are online

teplizumab

Editor's Picks